English | 简体中文 | 繁體中文 | 한국어 | 日本語
Wednesday, 9 October 2024, 19:29 HKT/SGT
Share:
CanSino Receives Another Strong Boost
- VLP-Polio Expected to Accelerate Development and Fill the Gap.

HONG KONG, Oct 9, 2024 - (ACN Newswire) - CanSino Biologics Inc. ("CanSinoBIO" or "the Company") has announced a milestone in its fight against polio. The company has received an additional financial boost, securing a grant exceeding US$17 million to propel its recombinant poliovirus vaccine ("VLP-Polio") project forward. This new funding, which builds on the initial funding received in October 2023, also encompasses potential related combined vaccine candidates.

In addition to the grant, CanSinoBIO has also obtained approval to start phase I/II clinical trials for the VLP-Polio vaccine in Indonesia, focusing on infants and toddlers in certain ages. This marks an important step forward in ensuring VLP-Polios safety and efficacy for the most vulnerable population.

Dr. Xuefeng Yu, Chairman and CEO of CanSinoBIO, expressed his gratitude for the continued support, stating, We are deeply honored by the foundation's ongoing trust and support. This recognition not only supports our innovation and production capabilities but also advances our commitment to improving global public health. We believe our innovative VLP-Polio vaccine will play a pivotal role in the global effort to eradicate polio.

Receives Over US$17 Million from Bill & Melinda Gates Foundation to Accelerate VLP-Polio Vaccine Development

This funding will further accelerate the clinical progress of the VLP-Polio vaccine, while the introduction of this vaccine candidate is expected to fill a gap in the market.

Leveraging the Company's profound expertise in protein structure design and virus-like particle (VLP) assembly technology, the VLP-Polio vaccine stands as a non-infectious alternative which eliminates the need for live viruses. This pioneering approach promises superior safety with comparable or superior immunogenicity, earning recognition from the World Health Organization ("WHO") as a pivotal tool for future polio eradication, particularly in the post-eradication era. This vaccine candidate holds immense significance in the global endeavor to control and eliminate polio, safeguarding millions of children and families from this devastating condition.

CanSinoBIO has been an avid participant in the WHO's polio eradication strategy, attentively tracking global disease prevention requirements. The funding received will further bolster CanSinoBIO's capacity to deliver innovative, high-quality, and affordable vaccines worldwide, aligning with the ambition of making advanced vaccine products accessible to all.



Topic: Press release summary Sectors: BioTech, Healthcare & Pharm, Clinical Trials
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Latest Press Releases
Chifeng Jilong Gold Mining, the Largest Non-State Owned Gold Producer in China, Announces Details of Proposed Listing on the Main Board of HKEX  
Feb 27, 2025 21:44 HKT/SGT
MovieCoin (MOV) Shaping the Future of Film Investment with Winvest Group  
Feb 27, 2025 21:30 HKT/SGT
The 17th Annual Global CSR & ESG Summit 2025 Concludes in Ho Chi Minh City, Setting New Standards in Sustainability  
Feb 27, 2025 20:47 HKT/SGT
Mazda Production and Sales Results for January 2025  
Thursday, February 27, 2025 5:20:00 PM
Toyota Submits Second Progress Report on Measures to Prevent Recurrence  
Thursday, February 27, 2025 5:00:00 PM
Blackrock Silver Steps Out and Hits Multiple +1 kg/t AgEq Intercepts in First Assays from Resource Expansion Program at Tonopah West  
Feb 27, 2025 17:00 HKT/SGT
Q2 Metals Announces Warrant Exercise for $7.6 Million  
Feb 27, 2025 16:48 HKT/SGT
HKTDC welcomes Hong Kong SAR's 2025-26 Budget  
Feb 27, 2025 16:46 HKT/SGT
Mazda Conducts Demonstration Operation of Cupola Melting Furnace using Biomass Fuel 100%  
Thursday, February 27, 2025 3:27:00 PM
Honda Selected as a CDP "Climate Change A List" Company for Second Consecutive Year  
Thursday, February 27, 2025 3:07:00 PM
More Press release >>
 Events:
More events >>
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575